Should Investors Be Worried About DermTech’s Decline From Its 52-Week Highs?

1 min read

DermTech (NASDAQ: DMTK) is trading well off its 52-week high of $84.49 per share while investors try to figure out how to value the prospects of the dermatology company. In this video from Motley Fool Live, recorded on March 8, Fool.com contributors Brian Orelli and Keith Speights talk about what the company is doing to grow sales of its melanoma test and why the recent decline shouldn’t be a big concern for long-term investors.

Continue reading

Leave a Reply

Your email address will not be published.

Previous Story

3 Hot Tech Growth Stocks You Can Buy Right Now

Next Story

This Space Infrastructure Supplier Is Going Public

Latest from Blog